Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Not Applicable

Active, not recruiting

• Conditions: Cardiovascular Abnormalities; Congenital Abnormalities; Heart Septal Defects, Atrial; Heart Diseases; Heart Defects, Congenital; Heart Septal Defect; Cardiovascular Diseases

• Registration Number: NCT04591392
• Lead Sponsor: atHeart Medical

Brief Summary

Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect

Detailed Description

Prospective, three-stage, single arm, multi-site, clinical investigation evaluating the safety and efficacy of the reSept ASD Occluder in treating clinically significant secundum ASD. Outcomes/endpoints of the clinical investigation will be compared with established performance goals for FDA approved transcatheter secundum ASD occluders.

Study Timeline

• Study First Submitted: 2020-10-06
• Study First Submitted QC: 2020-10-12
• Study First Posted: 2020-10-19
• Study Start: 2021-03-12
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-05
• Last Update Posted: 2025-05-07
• Primary Completion: 2027-03
• Study Completion: 2032-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

All responses must be Yes to be eligible:

1. Age < 85 years.
2. Body weight ≥ 15 kg / 33 lb.
3. Males and Females.
4. Clinically significant, isolated secundum ASD associated with a L-R shunt and signs of RV volume overload that, based upon the expertise of attending physicians requires treatment.
5. ASD of size 5 to 19 mm on screening diagnostic echocardiogram.
6. Isolated secundum ASD of size 8 to 22 mm on stop flow balloon diameter, based upon echocardiographic and fluoroscopic evidence obtained at procedure.
7. Able to take required medications: ASA (Aspirin), low dose (75-100 mg/day), 24 hours prior to and for 6 months following the procedure; Heparin intra-procedurally.
8. Adequate septal rim to support the device. The rim is considered inadequate if it measures less than 5mm in more than two views of a critical structure
9. Adequate defect margin to safely accommodate the selected size implant without interfering with adjacent cardiac structures (e.g., aorta, AV valves, ostia of the pulmonary veins, coronary sinus, or other critical structures), based on the IFU sizing guidance.
10. Capable of giving informed consent, or, for minors, consent of the parent or legal guardian, and willing to comply with the clinical investigation requirements.

Exclusion Criteria

All responses must be No to be eligible:

1. Pregnancy. Females with child-bearing potential are required to be tested for pregnancy prior to treatment, in accordance with the local institution's policy. For minor females, a pregnancy test will be done in accordance with the local institution's policy.
2. Any significant valve dysfunction that contraindicates ASD closure, or increased pulmonary vascular resistance/severe pulmonary hypertension.
3. Acquired pathological or congenital abnormalities of the cardiovascular system (other than isolated secundum ASD; e.g. congenital malformations, calcification, myocardial infarction, intracardiac thrombi, dilated cardiomyopathy, untreated coronary disease or CAD treated with a stent in the prior 12 months) being clinically significant, that would interfere with the conduct of the clinical investigation.
4. Subjects having undergone left sided structural heart interventions performed via transseptal access (e.g. Mitraclip, LAAO, percutaneous mitral valve replacement).
5. Evidence of thrombus in the left atrium, left atrial appendage, other cardiac chamber, or the inferior vena cava.
6. Sepsis or any other infection that was not successfully treated at least 30 days prior to device placement.
7. Active endocarditis or other infection(s) producing bacteremia.
8. History of atrial tachycardia, atrial fibrillation or flutter, AV block, or ventricular arrhythmia requiring antiarrhythmic medication, pacemaker or AICD.
9. Vasculature is of inadequate size to accommodate all procedural instrumentation.
10. Known allergy to investigational device components or medications, or other contraindication to clinical investigation medications (acetylsalicylic acid, heparin), including a documented history of bleeding, clotting or coagulation disorders, untreated ulcer or any other contraindications to acetylsalicylic acid or antiplatelet therapy.
11. Known hypercoagulable state.
12. Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation as well as any severe concurrent illness that would limit life expectancy (e.g. malignancies).
13. Currently an active subject in an investigational drug or device study that could confound the results of this study.
14. Patients who, in the opinion of the investigator, are inappropriate for inclusion into this clinical investigation or will not comply with requirements of the clinical investigation.
15. Are known to abuse drugs or alcohol.
16. Patients with the diagnosis of Patent Foramen Ovale (PFO).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Number of Subjects with CEC adjudicated Device- or Procedure-related SAEs	12 months	Incidence of subjects experiencing one or more serious device- or procedure related adverse events through the 12 month follow up visit, as adjudicated by the Clinical Events Committee (CEC)
Number of Subjects with 12-Month Composite Clinical Success	12 months	1. Clinically effective ASD closure, defined as no residual ASD or clinically insignificant residual ASD as determined by core laboratory review; and; 2. No re-intervention to treat the defect; and; 3. No device or procedure related serious adverse event.

Secondary Outcome Measures

Name	Time	Method
ASD Closure Success among Technical Success Subjects	1 month, 6 months and 12 months	Assessment of device performance will include closure success, among subjects that were technical successes (i.e. successful placement and release of the reSept ASD Occluder at the ASD), defined as no residual ASD or clinically insignificant residual ASD determined by echocardiography. Assessment of closure success at each follow up through the 12-month follow up will be assessed by TTE.
Number of Subjects with Device- or Procedure-related AEs	12 months	Incidence of subjects experiencing one or more non serious device- or procedure-related adverse events through the 12-month follow up visit.

Trial Locations

Locations (32)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Toronto General Hospital; 🇨🇦 Toronto, Canada

Service de Cardiologie Pédiatrique et Congénitale; 🇫🇷 Lille, France

Centre Hospitalier Universitaire Vaudois (CHUV); 🇨🇭 Lausanne, Switzerland

University Children's Hospital Zurich; 🇨🇭 Zurich, Switzerland

Children's Hospital of Los Angeles; 🇺🇸 Los Angeles, California, United States

Los Robles Regional Medical Center; 🇺🇸 Thousand Oaks, California, United States

Children's Hospital Colorado; 🇺🇸 Aurora, Colorado, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States

Joe DiMaggio Children's Hospital/Memorial Healthcare System; 🇺🇸 Hollywood, Florida, United States

Scroll for more (22 remaining)